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Background: The role of oral immunosuppressive therapy (OIT) after percutaneous
coronary intervention (PCI) and stenting still remains to be deﬁned. We sought to
evaluate the efﬁcacy and safety of oral administration of sirolimus or prednisone to
prevent in-stent restenosis.
Methods: We undertook a meta-analysis of trials in which PCI-patients were
randomly assigned to OIT or control therapy. The primary endpoint was the composite
of death/myocardial infarction (MI) or target lesion revascularization (TLR).
Secondary endpoints were the composite of death/MI, the individual components of
the primary endpoint and in-stent late lumen loss (LLL) at angiographic surveillance.
Results:We obtained individual data of seven trials enrolling 1,246 patients (OIT, n¼
608 versus control therapy, n¼ 638) with 1,456 coronary lesions. At a median follow-
up of 360 days [interquartile range 360-1440] OIT as compared to control therapy
signiﬁcantly reduced the risk of the composite primary endpoint (hazard ratio [95%
CI]¼ 0.62 [0.39-0.96], P¼ 0.03), without signiﬁcant difference in terms of death/MI
(0.84 [0.46-1.52], P¼ 0.57), death (1.12 [0.61-2.06], P¼ 0.71) and MI (0.67 [0.33-
1.38], P¼ 0.28). OIT as compared to control therapy signiﬁcantly reduced the risk of
TLR (0.55 [0.34-0.89], P¼ 0.01) as well as the degree of in-stent LLL (0.620.65 mm
versus 0.940.70 mm; mean difference 0.32 mm [0.22-0.42], P<0.001). The
proportion of patients complaining side effects associated with OIT was 13.4% and
1.1% permanently discontinued the therapy.
Conclusions: The use of oral immunosuppressive therapy as compared to control
therapy reduces the composite of death/myocardial infarction or target lesion revas-
cularization after stenting without safety issues. The advantage of oral immunosup-
pressive therapy is predominantly related to the lower risk of restenosis after
revascularization.
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Background: In atherosclerotic disease of infrapopliteal arteries, drug-eluting stents
(DES) improve patency rates as compared with plain balloon or bare metal stents
(BMS). However, the clinical impact of DES in this vascular territory remains still
uncertain.
Methods: We undertake an updated meta-analysis of randomized trials investigating
the outcomes of percutaneous revascularization with primary drug-eluting stenting in
patients with atherosclerotic disease of infrapopliteal arteries. We searched Medline,
EMBASE, the Cochrane Central Register of Controlled Trials (CENTRAL), scientiﬁc
session abstracts and relevant websites. Keywords were: "below the knee", "infra-
popliteal artery", "angioplasty", "drug-eluting stent(s)", "bare metal stent(s)", "trial",
and "randomized trial". Inclusion criteria were: (1) randomized design; (2) intention to
treat analysis; (3) a minimum of 6-month follow-up. Exclusion criteria were: (1)
vessels treated other than infrapopliteal arteries; (2) devices used other than DES, plain
balloon or BMS, and (3) duplicated data. The primary endpoint was target lesion
revascularization (TLR); secondary endpoints were restenosis, amputation and death.
Results: A total of 611 patients from 5 trials were randomly assigned to DES (n¼
294) versus control therapy (plain balloon/BMS, n¼ 307). Overall, median lesion
length was 26.8 mm [IQR 18.2-30.0] with a reference vessel diameter of 2.86 mm
[IQR 2.68-3.00]. At a median follow-up of 12 months [interquartile range 12-36],
DES reduced the risk of TLR (odds ratio [95% Conﬁdence interval] ¼ 0.31
[0.18–0.54], p<0.001), restenosis (0.25 [0.15–0.43], p<0.001) and amputation (0.50
[0.26–0.97], p¼ 0.04) without signiﬁcant difference in terms of death (0.81
[0.45–1.49], p¼ 0.50) versus control therapy.
Conclusions: In focal disease of infrapopliteal arteries, drug-eluting stent therapy
reduces the risk of reintervention and amputation as compared with plain balloon or
bare metal stent without impact on mortality at 1-year follow-up.B254 JACC Vol 62/18/Suppl B j October 27–NoTCT-843
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Background: Drug eluting balloons (DEB) have been developed to overcome the
limitations of drug eluting stent (DES), but clinical results of different studies about
DEB are still not consistent. Thus, we performed a meta-analysis to compare
outcomes of DEB and DES in coronary artery disease (CAD).
Methods: Medline/Web databases were searched for studies comparing DEB and
DES for obstructive CAD, reporting late lumen loss (LLL) and rates for overall
mortality, myocardial infarction (MI), stent thrombosis (ST) and target lesion revas-
cularization (TLR).
Results: Eight studies (1462 patients) were included in the meta-analysis. Compared
with DES, DEB treated patients showed non-signiﬁcantly higher LLL (weighted mean
difference [WMD] 0.32, 95% conﬁdence interval [CI] -0.15 to 0.78, P¼0.18) and non-
signiﬁcantly higher rate of binary restenosis (odds ratio [OR] 1.40 [0.68-2.48],
P¼0.36). Mortality (OR 1.13[0.54-2.37], P¼0.74), MI (OR 0.95, [0.50-1.80],
P¼0.87), ST (OR 1.12, [0.34-4.19], P¼0.77) and TLR rates (OR 1.19[0.60-2.38],
P¼0.61) were similar between the 2 treatments. A pre-speciﬁed meta-regression
analysis showed that LLL WMD and TLR OR were inversely correlated to the
prevalence of diabetes (P<0.0001) and directly correlated to reference coronary
diameters (P<0.001).
Conclusions: The present meta-analysis showed that, in comparison with DES, DEB
use was not followed by signiﬁcantly higher LLL, with similar clinical efﬁcacy and
safety. Thus DEB could be considered a reasonable alternative for interventional
cardiologists to limit the use of DES in selected clinical settings.
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Background: Thrombocytopenia (tcp) is associated with poor clinical outcomes in
patients receiving glycoprotein IIb/IIIa inhibitors (GPI), yet the extent of this risk and
differences between drugs and patient populations are uncertain. We evaluated the risk
of tcp associated with GPI compared to placebo.
Methods: Rate ratios were calculated for tcp (<100,000 platelets/mm3) and severe
tcp (<50,000 platelets/mm3) in 28 randomized large trials (>1000 patients) of GPI
versus placebo involving a total of 123,419 patients. We used meta-analysis tech-
niques to estimate the summary effect across all trials, in pre-speciﬁed subgroups, and
in sensitivity analyses to assess the robustness of the data.
Results: GPI use increases the rate of tcp (RR ¼ 1.63, 99%CI 1.48-1.79) and severe
tcp (RR ¼ 3.51, 99%CI 2.68-4.58). These ﬁnding are consistent by route of admin-
istration. Abciximab, tiroﬁban, xemiloﬁban, orboﬁban, and lotraﬁban demonstrated
signiﬁcantly increased tcp; eptiﬁbitide, lamiﬁban and sibraﬁban had non-signiﬁcant
increases compared to placebo. Patients with STEMI (RR 2.84, 99%CI 2.23-3.61) and
elective PCI (RR 2.78, 99%CI 1.76-4.40) had higher rates of tcp than patients with
nSTE-ACS (RR 1.41, 99%CI 1.25-1.58; p<0.001 for heterogeneity by subgroup).
Conclusions: The administration of GPI compared to placebo was associated with
a 63% increased risk of tcp (<100,000 platelets/mm3), and >3-fold increased risk of
severe tcp (<50,000 platelets/mm3). This corresponds to an average of 10-20 addi-
tional cases of tcp per 1000 patients given GPIs, of which are 6-7 are severe.vember 1, 2013 j TCT Abstracts/POSTER/Meta-Analyses and Reviews
